SANOFICONR · Sanofi Consumer Healthcare India Ltd · Biotechnology & Drugs
SANOFICONR · Sanofi Consumer Healthcare India Ltd · Biotechnology & Drugs
As of 05 Nov close
52-week range
34.5% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 52 days old
Revenue (latest Q)
₹236 Cr
Revenue YoY
PAT YoY
+13.3%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
26.9
P/S (TTM)
9.8
Sector P/E
36.3
Dividend yield
+1.9%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| SANOFICONR (this stock) | 39.8 | 26.9 | +28.0% | +76.5% | 0.06 | +1.9% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
stable
FII
falling 3q
MF
13.01% (-0.62pp)
falling 1q
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
No bulk/block deals in the last 12 months.
News timeline
No related news.
Concalls & investor presentations
AI-generatedKey takeaway: Sanofi Consumer Healthcare India Limited held its first Institutional Investor Meet on March 24, 2026, where management provided updates on the company's performance and strategic priorities. Managing Director Himanshu Bakshi highlighted the company's turnover of approximately ₹880 crore, with a Profit from Operations margin of 37% and a Return on Capital Employed (ROCE) of 62.5%. The company aims to reignite profitable growth through brand equity and increased investments in marketing. Bakshi noted the successful relaunch of previously recalled products and emphasized the importance of consumer education and engagement. The company reported a 21% increase in Revenue from Operations and a 33% rise in Profit After Tax (PAT) for the previous year. Management also discussed initiatives for social responsibility, including access to clean drinking water and environmental projects. The Q&A session addressed topics such as growth strategies, product pipelines, and market dynamics.
Management emphasized growth and successful initiatives during the investor meet.
Sourced from an exchange-filed transcript, dated 27 Mar 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Sanofi Consumer Healthcare India Limited provided an investor presentation on March 24, 2026, detailing its journey and future strategy. The presentation highlighted the company's leading brands and financial performance, reporting ₹8,784 million in revenue from operations and a 36.7% profit from operations for FY 2025. Management discussed the importance of brand equity and consumer healthcare approaches, emphasizing a synergy between prescriptions and self-choice. The company outlined its strategy to enhance healthcare professional engagement and consumer access, aiming to double doctor reach and increase direct retail coverage. Additionally, the presentation mentioned the company's commitment to social responsibility, including initiatives like Project Amrit and B Corp certification. Management set a vision to become the best fast-moving consumer healthcare (FMCH) company in India, focusing on leveraging digital and AI for improved decision-making and execution.
The presentation emphasized growth opportunities and strategic initiatives for enhancing performance.
Sourced from an exchange-filed presentation, dated 24 Mar 2026. Summary is RedixFi-generated and distinct from investment advice.
AI Summary of Annual Report
AI-generatedSanofi Consumer Healthcare India Limited (SANOFICONR) completed its first full year of independent operations in FY2025, focusing on stability and momentum. The company executed its strategy effectively, strengthening access to healthcare solutions and driving consumer pull through demand generation. Key managerial changes included the appointment of Mr. Richard D’souza as CFO in October 2025. The company transitioned to 100% green energy and reported no material legal, regulatory, or compliance issues. No significant orders from regulators or courts were noted, and there were no defaults or liquidity concerns. The company also disclosed related party transactions with Opella Healthcare International SAS, which were within regulatory thresholds and did not require shareholder approval.
- Completed first full year of independent operations with focus on stability and momentum.
- Appointed Mr. Richard D’souza as CFO effective 16th October 2025.
- Transitioned to 100% green energy for operations.
- No material legal, regulatory, or compliance issues reported.
- Related party transactions with Opella Healthcare International SAS were within regulatory thresholds.
Key takeaway: Sanofi Consumer Healthcare India Limited demonstrated stable operations and compliance in FY2025, with no major risks or defaults reported, and strategic focus on sustainability and consumer engagement.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Auditor Qualification (1 item)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Auditor Qualification
1 occurrenceRecent (last 12 months)
The auditors, M/s. Kalyaniwalla & Mistry LLP, resigned from their position as Statutory Auditors of the Company on 30th April 2026 before completing their term, resulting in a casual vacancy that required shareholder approval.
Routine disclosures
Contingent Liability
2 occurrencesRecent (last 12 months)
Sanofi Consumer Healthcare India Limited has a contingent liability of 15 M in the form of a bank guarantee issued to the Custom Department as of December 2024.
Earlier (1-3 years ago)
The company has a contingent liability of ₹6 MINR in the form of a bank guarantee issued to the Custom Department as of December 2023.
Related-Party Transaction
2 occurrencesRecent (last 12 months)
The company obtained shareholder approval for material related party transactions with Sanofi India Limited, Opella Healthcare India Private Limited, and Opella Healthcare International SAS through postal ballot.
Earlier (1-3 years ago)
The company sought shareholders' consent for a material related party transaction, and the Postal Ballot process was conducted in compliance with relevant regulations.
Management & Board Governance
1 occurrenceRecent (last 12 months)
Ms. Maithilee Mistry resigned as Whole-time Director and Chief Financial Officer on 5th May 2025.